These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 9696006

  • 1. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J.
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [Abstract] [Full Text] [Related]

  • 2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 3. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U.
    Hepatogastroenterology; 2003 Jul; 50(54):1753-5. PubMed ID: 14696397
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A.
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [Abstract] [Full Text] [Related]

  • 5. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
    Gülberg V, Gerbes AL.
    Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
    [Abstract] [Full Text] [Related]

  • 6. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.
    Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM.
    Hepatology; 1995 Mar; 21(3):709-16. PubMed ID: 7875668
    [Abstract] [Full Text] [Related]

  • 7. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-Layrargues G.
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [Abstract] [Full Text] [Related]

  • 8. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt.
    Spahr L, Fenyves D, N'Guyen VV, Roy L, Legault L, Dufresne MP, Pomier-Layrargues G.
    Am J Gastroenterol; 1995 Jul; 90(7):1169-71. PubMed ID: 7611221
    [Abstract] [Full Text] [Related]

  • 9. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A, Gulberg V, Sauter G, Waggershauser T, Reiser M, Gerbes AL.
    Hepatogastroenterology; 1998 Jul; 45(24):2315-21. PubMed ID: 9951915
    [Abstract] [Full Text] [Related]

  • 10. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E, Wengert A, Fleig WE.
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
    Wong W, Liu P, Blendis L, Wong F.
    Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
    [Abstract] [Full Text] [Related]

  • 13. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D, Trägner P, Wawer A, Porst H, Daniel WG, Gross P.
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T.
    Gut; 2000 Aug; 47(2):288-95. PubMed ID: 10896924
    [Abstract] [Full Text] [Related]

  • 16. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis.
    Biecker E, Roth F, Heller J, Schild HH, Sauerbruch T, Schepke M.
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):846-52. PubMed ID: 17873607
    [Abstract] [Full Text] [Related]

  • 17. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M, Cholongitas E, Tibballs J, Burroughs A, Patch D.
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J.
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.